A Phase Ⅱa Study of ND-003 Tablets in Patients With Idiopathic Pulmonary Fibrosis

ND-003 Tablets · Фаза 2

ID реестра
NCT07929948
Фаза
Фаза 2
Статус
Набор по приглашению
Препарат / вмешательство
ND-003 Tablets
Спонсор
Shenzhen NewDEL Biotech, Co., Ltd
Набор участников
10
Центры
1

Об исследовании

Idiopathic pulmonary fibrosis (IPF) is a chronic, progressive, fibrosing interstitial lung disease that predominantly affects middle-aged and older adults. Progressive replacement of normal lung parenchyma by extracellular matrix and destruction of the alveolar architecture lead to reduced lung compliance and impaired gas exchange. Clinically, IPF is characterized by progressively worsening dyspnea, restrictive ventilatory impairment, impaired gas exchange, hypoxemia, and, in advanced cases, respiratory failure. Current pharmacological treatment of IPF is primarily based on antifibrotic therapy. Pirfenidone and nintedanib were the first two antifibrotic agents approved for IPF and have been shown to slow the decline in forced vital capacity (FVC) through different mechanisms of action. Pi

Открыть NCT07929948 на ClinicalTrials.gov →

Медицинская оговорка. Эта страница обобщает публичные данные исследования NCT07929948 только для информации. Это не медицинская рекомендация, не одобрение и не предложение участия. Проверяйте детали на ClinicalTrials.gov и у квалифицированного врача.